Eli Lilly’s Taltz shows superiority over AbbVie’s Humira

pharmafile | December 18, 2018 | News story | Manufacturing and Production Eli Lilly, Humira, Taltz, arthritis, immune system 

A study has found that Eli Lilly’s Taltz (ixekizumab) met the primary, and all secondary endpoints, in patients with active psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drug (DMARD)-naïve when compared to AbbVie’s Humira.

 The Phase IIIb/IV SPIRIT-H2H study, 566 patients with active PsA demonstrates Taltz’s superiority over the world’s bestselling drug.

Lotus Mallbris, vice president of immunology development at the Indian-based firm suggested that “these results provide evidence that Taltz can be used as a first-line biologic treatment for patients with active psoriatic arthritis.”

Last month Eli Lilly revealed that sales of Taltz for the third quarter of this year shot up by as much as 74 percent year-over-year increasing to a total of $263.9 million, beating forecasts. Overall, the IL-17 inhibitor had total revenue of $560 million in 2017.

Louis Goss

Related Content

Eli Lilly to acquire POINT Biopharma

Eli Lilly and POINT Biopharma have announced a definitive agreement for Lilly to acquire POINT …

FDA approves Eli Lilly and Boehringer Ingelheim’s Jardiance for chronic kidney disease treatment

Eli Lilly and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) …

Eli Lilly shares topline results from LIBRETTO-531 trial for Retevmo

Eli Lilly has announced topline results from the LIBRETTO-531 study assessing Retevmo (selpercatinib) as an …

Latest content